Dyax. Affimed has a royalty free cross-licensing agreement for the use of their phage display technology. In return, Dyax has the right to use our IgM library IP for the generation of IgM-based libraries. The rights to make or use such a library cannot be transferred to a third party.
Appears in 2 contracts
Sources: License Agreement (Affimed Therapeutics B.V.), License Agreement (Affimed Therapeutics B.V.)